Prévisions

Actualités Accéder au fil d'actualités

Roche: lung cancer candidate Divarasib outperforms approved therapies in study

In a registration-relevant head-to-head trial against Lumakras (Amgen) and Krazati (Mirati Therapeutics), Divarasib achieved significant improvements in progression-free survival and overall survival. No new safety signals were observed. Roche plans to submit the data to regulators and present the results at a medical congress. » Plus sur finanzen.net
Roche: FDA accepts Roche's approval application for Giredestrant for review

The FDA has accepted the approval application for Roche's drug candidate Giredestrant for review. This brings a potential U.S. approval for Giredestrant one step closer. Further regulatory steps and decisions remain pending. » Plus sur finanzen.net
Roche announces new data on obesity portfolio

Roche has announced the release of new data from its obesity portfolio. Details on study results or timelines were not mentioned in the text, and investors are awaiting further information on the efficacy and regulatory approval prospects of the treatments. » Plus sur finanzen.net

En 2026, Roche PS a déjà versé 10,81€ de dividendes. Le dernier versement a eu lieu en mars.

Au dernier trimestre, Roche PS a réalisé un chiffre d'affaires de 32,71Md€ et un bénéfice net de 7,40Md€